Article Text
Abstract
Objective To examine Hispanic/Latino representation in diabetes cardiovascular outcomes trials for novel antidiabetic drugs.
Research design and methods We compared Hispanic/Latino representation, age, gender and body mass index in diabetes cardiovascular outcomes trials published from January 2008 to October 2018 to Hispanic adults with diabetes in the National Health Examination and Nutrition Survey over the same time period.
Results Hispanics/Latinos comprised 18.5 % of trial subjects, which was similar to the proportion of US adults with diabetes who identify as Hispanic. Trial subjects were significantly younger, more likely to be female, and more obese than US Hispanics/Latinos. At least 10 different Latin American countries and territories were represented across the 10 trials.
Conclusions US Hispanics/Latinos differ from subjects in diabetes cardiovascular outcomes trials, which may limit generalizability of trial results.
- type 2 diabetes
- hispanic
- disparities
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Footnotes
Contributors ATTK organized the analysis, drafted and edited the manuscript. KM assisted in data analysis and editing of the manuscript. MO provided content expertise in developing the study concept and provided edits to drafts. MEB provided content expertise in developing the study concept and provided edits to drafts. JS conceived the study, provided oversight, facilitated development of the study concept, and provided edits to drafts.
Funding No funding was received for this project. Michael Bowen receives research support from a K23 career development award from the National Institute of Diabetes and Digestive and Kidney Diseases (DK104065). Dr. Sussmanis supported by VA CDA 13-021 and VA IIR 15-432. Drs. Kelley and Mizokami-Stout are supported by the National Clinician Scholars Program at the University of Michigan.
Conflicts of interest MO has received consulting fees from United Healthcare Services and Novo Nordisk that are unrelated this work.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request.